Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Org Chem ; 84(8): 4723-4734, 2019 04 19.
Artigo em Inglês | MEDLINE | ID: mdl-30412402

RESUMO

ABBV-168 is a dihalogenated nucleotide under investigation for the treatment of hepatitis C virus. Three synthetic routes aimed at achieving the stereoselective installation of the C2' gem-Br,F substitution and subsequent Vorbruggen glycosylation were explored to prepare the penultimate nucleoside intermediate. Development culminated in a route to ABBV-168 featuring a de novo chromatography-free furanose synthesis, protecting group-directed Vorbruggen glycosylation, and highly selective phosphoramidation to furnish the API.


Assuntos
Antivirais/farmacologia , Hepacivirus/efeitos dos fármacos , Hepatite C/tratamento farmacológico , Nucleotídeos/farmacologia , Antivirais/síntese química , Antivirais/química , Humanos , Testes de Sensibilidade Microbiana , Conformação Molecular , Nucleotídeos/síntese química , Nucleotídeos/química
2.
Int J Pharm ; 665: 124656, 2024 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-39245087

RESUMO

Conventional solid oral dosage form development is not typically challenged by reliance on an amorphous drug substance as a direct ingredient in the drug product, as this may result in product development hurdles arising from process design and scale-up, control of physical quality attributes, drug product processability and stability. Here, we present the Chemistry, Manufacturing and Controls development journey behind the successful commercialization of an amorphous drug substance, Elagolix Sodium, a first-in-class, orally active gonadotropin-releasing hormone antagonist. The reason behind the lack of crystalline state was assessed via Molecular Dynamics (MD) at the molecular and inter-molecular level, revealing barriers for nucleation due to prevalence of intra-molecular hydrogen bond, repulsive interactions between active pharmaceutical ingredient (API) molecules and strong solvation effects. To provide a foundational basis for the design of the API manufacturing process, we modeled the solvent-induced plasticization behavior experimentally and computationally via MD for insights into molecular mobility. In addition, we applied material science tetrahedron concepts to link API porosity to drug product tablet compressibility. Finally, we designed the API isolation process, incorporating computational fluid dynamics modeling in the design of an impinging jet mixer for precipitation and solvent-dependent glass transition relationships in the cake wash, blow-down and drying process, to enable the consistent manufacture of a porous, non-sintered amorphous API powder that is suitable for robust drug product manufacturing.


Assuntos
Simulação de Dinâmica Molecular , Pirimidinas , Comprimidos , Administração Oral , Pirimidinas/química , Pirimidinas/administração & dosagem , Composição de Medicamentos/métodos , Cristalização , Química Farmacêutica/métodos , Porosidade , Ligação de Hidrogênio , Estabilidade de Medicamentos , Hidrocarbonetos Fluorados
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA